The Female Reproductive Tract Microbiome and Cancerogenesis: A Review Story of Bacteria, Hormones, and Disease
暂无分享,去创建一个
R. Anghel | R. Mitrica | G. Serbanescu | Ș. Marinescu | L. Galeș | Diana Maria Bran | S. Marinescu | O. Trifănescu | R. Trifănescu | B. Tanase | Laurentiu Valcauan | Bogdan Tanase
[1] Xin Li,et al. Roles of vaginal flora in human papillomavirus infection, virus persistence and clearance , 2023, Frontiers in Cellular and Infection Microbiology.
[2] Gun-Hee Kim,et al. Anti-Tumor Effects of Heat-Killed L. reuteri MG5346 and L. casei MG4584 against Human Colorectal Carcinoma through Caspase-9-Dependent Apoptosis in Xenograft Model , 2022, Microorganisms.
[3] C. Allaire,et al. Intricate Connections between the Microbiota and Endometriosis , 2021, International journal of molecular sciences.
[4] P. Cassoni,et al. Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions. , 2021, ACS infectious diseases.
[5] J. Hasty,et al. The microbiome and human cancer , 2021, Science.
[6] J. Gonzalez-Bosquet,et al. Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome , 2021, Cancers.
[7] Huanrong Li,et al. The Interaction Between Microorganisms, Metabolites, and Immune System in the Female Genital Tract Microenvironment , 2020, Frontiers in Cellular and Infection Microbiology.
[8] Li Tang,et al. Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer , 2020, International journal of cancer.
[9] Xiaofeng Mu,et al. Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection. , 2020, Microbial pathogenesis.
[10] V. Bae-Jump,et al. Diet and gut microbiome interactions in gynecologic cancer. , 2020, Gynecologic oncology.
[11] Jan Claesen,et al. Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy , 2020, bioRxiv.
[12] S. Chilakapati,et al. Microbiome and cancer immunotherapy. , 2020, Current opinion in biotechnology.
[13] Jingbo Peng,et al. Vaginal microbiomes and ovarian cancer: a review. , 2020, American journal of cancer research.
[14] Rob Knight,et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.
[15] Z. Ilhan,et al. The microbiome and gynaecological cancer development, prevention and therapy , 2020, Nature Reviews Urology.
[16] K. Konstantinidis,et al. Comparison of vaginal microbiota in gynecologic cancer patients pre‐ and post‐radiation therapy and healthy women , 2019, Cancer medicine.
[17] L. Engstrand,et al. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta‐analysis , 2019, BJOG : an international journal of obstetrics and gynaecology.
[18] M. Momeny,et al. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid) , 2019, Cancer Chemotherapy and Pharmacology.
[19] R. Pezo,et al. Untapped “-omics”: the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment , 2019, Breast Cancer Research and Treatment.
[20] G. Bonaccorsi,et al. Atopobium vaginae And Porphyromonas somerae Induce Proinflammatory Cytokines Expression In Endometrial Cells: A Possible Implication For Endometrial Cancer? , 2019, Cancer management and research.
[21] Hao Xu,et al. The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice. , 2019, Life sciences.
[22] A. Ryan,et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. , 2019, The Lancet. Oncology.
[23] Yuli Chen,et al. Intestinal dysbiosis promotes epithelial-mesenchymal transition by activating tumor-associated macrophages in ovarian cancer , 2019, Pathogens and disease.
[24] Guoxing Fu,et al. The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ , 2019, bioRxiv.
[25] S. Fernando,et al. Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions , 2019, mBio.
[26] Junbo Hu,et al. The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients , 2019, Scientific Reports.
[27] A. Mitra,et al. Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study , 2019, BMC Women's Health.
[28] M. Torcia. Interplay among Vaginal Microbiome, Immune Response and Sexually Transmitted Viral Infections , 2019, International journal of molecular sciences.
[29] V. Azevedo,et al. Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP , 2018, Scientific Reports.
[30] V. Azevedo,et al. Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP , 2018, Scientific Reports.
[31] C. A. Speck-Hernandez,et al. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. , 2018, Cancer research.
[32] A. Mariani,et al. Case for a role of the microbiome in gynecologic cancers: Clinician's perspective , 2018, The journal of obstetrics and gynaecology research.
[33] C. Bolego,et al. Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment , 2018, Biochemical pharmacology.
[34] R. Montironi,et al. Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. , 2018, European urology.
[35] Z. Ilhan,et al. Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics. , 2018, Maturitas.
[36] Chang H. Kim. Immune regulation by microbiome metabolites , 2018, Immunology.
[37] A. Watson,et al. Could Fecal Transplantation Become Part of PD-1-Based Immunotherapy, Due to Effects of the Intestinal Microbiome? , 2018, Gastroenterology.
[38] M. Yuan,et al. Endometriosis induces gut microbiota alterations in mice , 2018, Human reproduction.
[39] M. Herbst-Kralovetz,et al. Uterine Microbiota: Residents, Tourists, or Invaders? , 2018, Front. Immunol..
[40] Yulong Yin,et al. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism , 2018, Front. Cell. Infect. Microbiol..
[41] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[42] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[43] A. Pierangeli,et al. Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection , 2018, BMC Infectious Diseases.
[44] Z. Kokot,et al. Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis , 2017, International journal of molecular sciences.
[45] T. Hasan,et al. Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis , 2017, Molecular Cancer Therapeutics.
[46] M. Bogdanov,et al. Biogenesis, transport and remodeling of lysophospholipids in Gram-negative bacteria. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[47] M. Herbst-Kralovetz,et al. Estrogen-gut microbiome axis: Physiological and clinical implications. , 2017, Maturitas.
[48] D. Cavalieri,et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection , 2017, Scientific Reports.
[49] G. Park,et al. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells. , 2017, Oncology reports.
[50] K. Bernstein,et al. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. , 2017, Obstetrics and gynecology.
[51] Zhi Wei,et al. The ovarian cancer oncobiome , 2017, Oncotarget.
[52] Ian D. Wilson,et al. Gut microbiota modulation of chemotherapy efficacy and toxicity , 2017, Nature Reviews Gastroenterology &Hepatology.
[53] Chen Hu,et al. Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway , 2017, OncoTargets and therapy.
[54] Junling Zhang,et al. Faecal microbiota transplantation protects against radiation‐induced toxicity , 2017, EMBO molecular medicine.
[55] A. Patterson,et al. The aryl hydrocarbon receptor as a moderator of host-microbiota communication. , 2017, Current opinion in toxicology.
[56] J. Venter,et al. The Human Microbiome and Cancer , 2017, Cancer Prevention Research.
[57] So-Jin Shin,et al. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell , 2016, Journal of gynecologic oncology.
[58] L. Kiemeney,et al. Systematic Reviews and Meta- and Pooled Analyses Pelvic In fl ammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies , 2016 .
[59] S. Lynch,et al. The Human Intestinal Microbiome in Health and Disease. , 2016, The New England journal of medicine.
[60] R. Dunn,et al. Lactobacilli Dominance and Vaginal pH: Why Is the Human Vaginal Microbiome Unique? , 2016, Front. Microbiol..
[61] A. Mariani,et al. Potential contribution of the uterine microbiome in the development of endometrial cancer , 2016, Genome Medicine.
[62] I. Vergote,et al. The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. , 2016, Anticancer research.
[63] M. Herbst-Kralovetz,et al. Menopause and the vaginal microbiome. , 2016, Maturitas.
[64] L. Forney,et al. Unraveling the Dynamics of the Human Vaginal Microbiome , 2016, The Yale journal of biology and medicine.
[65] J. Marrazzo,et al. The Vaginal Microbiome: Current Understanding and Future Directions. , 2016, The Journal of infectious diseases.
[66] So-Jin Shin,et al. The effect of salinomycin on ovarian cancer stem-like cells , 2016, Obstetrics & gynecology science.
[67] R. Xavier,et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands , 2016, Nature Medicine.
[68] A. Burguete-García,et al. Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study , 2016, PloS one.
[69] T. Hope,et al. Glycogen Levels in Undiluted Genital Fluid and Their Relationship to Vaginal pH, Estrogen, and Progesterone , 2016, PloS one.
[70] F. Markowetz,et al. Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. , 2016, Cancer research.
[71] F. Tekşen,et al. Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3) , 2016, Tumor Biology.
[72] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[73] J. K. Nicholson,et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity , 2015, Scientific Reports.
[74] Jens Nielsen,et al. The gut microbiota modulates host amino acid and glutathione metabolism in mice , 2015 .
[75] X. Hua,et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. , 2015, Journal of the National Cancer Institute.
[76] J. Ravel,et al. The vocabulary of microbiome research: a proposal , 2015, Microbiome.
[77] Wendy S. Garrett,et al. Cancer and the microbiota , 2015, Science.
[78] F. Sotgia,et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease , 2015, Oncotarget.
[79] S. Badar,et al. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. , 2015, American journal of cancer research.
[80] G. Rabinovich,et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. , 2015, Cancer cell.
[81] G. Trinchieri,et al. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy , 2015, European journal of immunology.
[82] G. Lou,et al. Large‐scale profiling of metabolic dysregulation in ovarian cancer , 2014, International journal of cancer.
[83] Sandhya Kortagere,et al. Symbiotic Bacterial Metabolites Regulate Gastrointestinal Barrier Function via the Xenobiotic Sensor PXR and Toll‐like Receptor 4 , 2014, Immunity.
[84] F. Benencia,et al. Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies , 2014, Front. Immunol..
[85] R. Schwabe,et al. The Microbiome and Cancer , 2021, Gut Feelings.
[86] A. De Luca,et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. , 2013, Immunity.
[87] L. Forney,et al. Influence of Vaginal Bacteria and d- and l-Lactic Acid Isomers on Vaginal Extracellular Matrix Metalloproteinase Inducer: Implications for Protection against Upper Genital Tract Infections , 2013, mBio.
[88] So-Jin Shin,et al. Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells. , 2013, Cancer epidemiology.
[89] Eun Jin Seo,et al. TAZ Mediates Lysophosphatidic Acid-Induced Migration and Proliferation of Epithelial Ovarian Cancer Cells , 2013, Cellular Physiology and Biochemistry.
[90] S. Badar,et al. Minocycline Targets the NF-κB Nexus through Suppression of TGF-β1-TAK1-IκB Signaling in Ovarian Cancer , 2013, Molecular Cancer Research.
[91] S. Kjaer,et al. Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors , 2013, Cancer Causes & Control.
[92] D. Morris,et al. Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies , 2013, PloS one.
[93] S. Badar,et al. Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways. , 2013, Gynecologic oncology.
[94] So-Jin Shin,et al. Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells. , 2013, Anticancer research.
[95] Chang-Yun Lin,et al. The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma , 2013, Molecular oncology.
[96] Tao Zhang,et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. , 2013, Journal of proteome research.
[97] J. Goedert,et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study , 2012, Journal of Translational Medicine.
[98] M. Kleerebezem,et al. The microbiota and the gut-brain axis: insights from the temporal and spatial mucosal alterations during colonisation of the germfree mouse intestine. , 2012, Beneficial microbes.
[99] K. Jeong,et al. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion , 2012, Oncogene.
[100] H. Flint,et al. Phylogenetic distribution of genes encoding β-glucuronidase activity in human colonic bacteria and the impact of diet on faecal glycosidase activities. , 2012, Environmental microbiology.
[101] J. Qiao,et al. Bacterial vaginosis is conducive to the persistence of HPV infection , 2012, International journal of STD & AIDS.
[102] Tao Zhang,et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[103] Katherine H. Huang,et al. Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.
[104] Zaid Abdo,et al. Temporal Dynamics of the Human Vaginal Microbiota , 2012, Science Translational Medicine.
[105] Ming-zhu Yin,et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform , 2012, Acta oncologica.
[106] T. Dinan,et al. An effective dietary method for chronic tryptophan depletion in two mouse strains illuminates a role for 5-HT in nesting behaviour , 2012, Neuropharmacology.
[107] G. Senthilkumar,et al. Viral and bacterial aetiologies of epithelial ovarian cancer , 2012, European Journal of Clinical Microbiology & Infectious Diseases.
[108] J. Paavonen. Chlamydia trachomatis infections of the female genital tract: State of the art , 2012, Annals of medicine.
[109] Liang Zhou,et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. , 2012, Immunity.
[110] H. Tilg,et al. Too much fat for the gut's microbiota , 2012, Gut.
[111] A. Stapleton,et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[112] Joris Meys,et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis , 2011, BMC infectious diseases.
[113] S. Shiboski,et al. Phase 2a Study Assessing Colonization Efficiency, Safety, and Acceptability of Lactobacillus crispatus CTV-05 in Women With Bacterial Vaginosis , 2010, Sexually transmitted diseases.
[114] Alexander G. Gray,et al. Rapid Mass Spectrometric Metabolic Profiling of Blood Sera Detects Ovarian Cancer with High Accuracy , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[115] T. Drewa,et al. The influence of ciprofloxacin on hamster ovarian cancer cell line CHO AA8. , 2010, Acta poloniae pharmaceutica.
[116] J. Doré,et al. A metagenomic β-glucuronidase uncovers a core adaptive function of the human intestinal microbiome , 2010, Proceedings of the National Academy of Sciences.
[117] Y. Ainmelk,et al. Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes , 2010, Journal of ovarian research.
[118] J. Hurst,et al. Lysophosphatidic Acid Stimulates Cell Growth by Different Mechanisms in SKOV-3 and Caov-3 Ovarian Cancer Cells: Distinct Roles for Gi- and Rho-Dependent Pathways , 2009, Pharmacology.
[119] H. Tilg,et al. Obesity and the microbiota. , 2009, Gastroenterology.
[120] S. Mazmanian,et al. The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.
[121] W. R. Wikoff,et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.
[122] A. Pierangeli,et al. Human Papillomaviruses and genital co-infections in gynaecological outpatients , 2009, BMC infectious diseases.
[123] Y. Taketani,et al. Interleukin (IL)-17A stimulates IL-8 secretion, cyclooxygensase-2 expression, and cell proliferation of endometriotic stromal cells. , 2008, Endocrinology.
[124] C. Rock,et al. Membrane lipid homeostasis in bacteria , 2008, Nature Reviews Microbiology.
[125] C. Czuprynski,et al. The Aryl Hydrocarbon Receptor Is Required for Optimal Resistance to Listeria monocytogenes Infection in Mice1 , 2007, The Journal of Immunology.
[126] G. Mills,et al. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. , 2007, International journal of oncology.
[127] R. Chen,et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.
[128] G. Mills,et al. Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer , 2006 .
[129] J. Papp,et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. , 2005, American journal of epidemiology.
[130] S. Hillier,et al. Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. , 2005, The Journal of infectious diseases.
[131] Yan Xu,et al. A novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[132] G. Wilbanks,et al. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. , 1999, Gynecologic oncology.
[133] G. Mills,et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[134] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[135] B. Piura,et al. Tumor necrosis factor-alpha and interleukin-6 are differently expressed by fresh human cancerous ovarian tissue and primary cell lines. , 1998, European cytokine network.
[136] B. Piura,et al. Distinct patterns of expression of interleukin-1 alpha and beta by normal and cancerous human ovarian tissues. , 1997, European cytokine network.
[137] G. Mills,et al. Lysophospholipids activate ovarian and breast cancer cells. , 1995, The Biochemical journal.
[138] M. Yokoyama,et al. Microbial metabolites of tryptophan in the intestinal tract with special reference to skatole. , 1979, The American journal of clinical nutrition.